Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1179-190X
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review ; volume:35 ; number:2 ; day:17 ; month:2 ; year:2021 ; pages:175-186 ; date:3.2021
BioDrugs ; 35, Heft 2 (17.2.2021), 175-186, 3.2021

Creator
Chessa, Elisabetta
Piga, Matteo
Floris, Alberto
Congia, Mattia
Cangemi, Ignazio
Mathieu, Alessandro
Cauli, Alberto
Contributor
SpringerLink (Online service)

DOI
10.1007/s40259-021-00467-w
URN
urn:nbn:de:101:1-2021040120213407267354
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Chessa, Elisabetta
  • Piga, Matteo
  • Floris, Alberto
  • Congia, Mattia
  • Cangemi, Ignazio
  • Mathieu, Alessandro
  • Cauli, Alberto
  • SpringerLink (Online service)

Other Objects (12)

Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions

Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions

Clinical advances in immunotherapy for immune-mediated glomerular diseases

Clinical advances in immunotherapy for immune-mediated glomerular diseases

Immune-mediated glomerular diseases: new basic concepts and clinical implications

Immune-mediated glomerular diseases: new basic concepts and clinical implications

Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases

Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases

Inflammaging and Frailty in Immune-Mediated Rheumatic Diseases: How to Address and Score the Issue

Inflammaging and Frailty in Immune-Mediated Rheumatic Diseases: How to Address and Score the Issue

Serum C-reactive protein concentrations in Nova Scotia Duck Tolling Retrievers with immune-mediated rheumatic disease

Serum C-reactive protein concentrations in Nova Scotia Duck Tolling Retrievers with immune-mediated rheumatic disease

Ultrasound and magnetic resonance imaging as diagnostic tools for sarcopenia in immune-mediated rheumatic diseases (IMRDs)

Ultrasound and magnetic resonance imaging as diagnostic tools for sarcopenia in immune-mediated rheumatic diseases (IMRDs)

Biologics in therapy

Zeitschrift

Biologics in therapy

Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs

Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs

Socioeconomic factors and COVID-19 mortality in immune-mediated rheumatic diseases patients: regional analysis from Argentina, Mexico and Brazil

Socioeconomic factors and COVID-19 mortality in immune-mediated rheumatic diseases patients: regional analysis from Argentina, Mexico and Brazil

Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force

Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force

Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis

Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis

Related objects